Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Acyclovir** is a synthetic guanine nucleoside analogue antiviral drug originally developed by GSK and widely available as branded and generic products. It is selectively activated in herpesvirus-infected cells by viral thymidine kinase and subsequently converted by host enzymes to acyclovir triphosphate. The active metabolite competitively inhibits herpesvirus DNA polymerase and causes viral DNA-chain termination, suppressing replication of herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus. It is used systemically and topically for herpes simplex infections, genital herpes, herpes zoster, varicella, herpes labialis, severe mucocutaneous herpesvirus infection in immunocompromised patients, and severe invasive HSV disease including HSV encephalitis and neonatal herpes. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0910335b-6796-459f-b97e-d7ef5439a060))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acyclovir.